About this Research Topic
According to Le Louët H., adverse drug reactions are among the leading causes of death in the world and constitute a public health problem. The field of pharmacogenetics and pharmacogenomics is a field that is increasingly expanding and of increasing interest to the scientific community.
Despite advances in science, the field of pharmacogenetics and pharmacogenomics is largely yet to be explored, especially at the drug receptor and transport levels.
There are many reasons that make the problem of adverse effects and pharmacogenetics one of the most important debates in the scientific field. Most of the variations occur due to drug metabolizing enzymes (DMEs). DME genes and the DME receptor and drug transporter genes can be considered "modifier genes” and can also determine the onset of some neurological and oncological diseases.
The purpose of this Research Topic is to provide a contribution to the scientific community in this regard. We hope that contributions to this Research Topic progress the field of pharmacogenetics and pharmacogenomics also from a toxicological, forensic, and public health standpoint. This Topic concerns all branches of medicine, from oncohematology to forensic toxicology, from cardiology to anesthesia.
This Topic will be open to the submission of (mini reviews/reviews etc.)
Please note that:
- If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities, and additional clinical information and assessment of clinical response/effects should be included.
- If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided.
- Studies related to natural compounds, herbal extracts, or traditional medicine products, will not be included in this Research Topic.
Despite advances in science, the field of pharmacogenetics and pharmacogenomics is largely yet to be explored, especially at the drug receptor and transport levels.
There are many reasons that make the problem of adverse effects and pharmacogenetics one of the most important debates in the scientific field. Most of the variations occur due to drug metabolizing enzymes (DMEs). DME genes and the DME receptor and drug transporter genes can be considered "modifier genes” and can also determine the onset of some neurological and oncological diseases.
The purpose of this Research Topic is to provide a contribution to the scientific community in this regard. We hope that contributions to this Research Topic progress the field of pharmacogenetics and pharmacogenomics also from a toxicological, forensic, and public health standpoint. This Topic concerns all branches of medicine, from oncohematology to forensic toxicology, from cardiology to anesthesia.
This Topic will be open to the submission of (mini reviews/reviews etc.)
Please note that:
- If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities, and additional clinical information and assessment of clinical response/effects should be included.
- If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided.
- Studies related to natural compounds, herbal extracts, or traditional medicine products, will not be included in this Research Topic.
Keywords: reviews, drug transporters, DMEs
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
